Improvement in treatment adherence in patients with chronic hepatitis C

Practical Gastroenterology

Volumn 32, Issue 12, 2008, Pages 31-42

  Palmer, Melissa ^a  

^a Liver Center of Long Island   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; DRONABINOL; HISTAMINE H2 RECEPTOR ANTAGONIST; LOPERAMIDE; METOCLOPRAMIDE; PEGINTERFERON ALPHA2B; PROTON PUMP INHIBITOR; RIBAPAK; RIBASPHERE; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTICLE; BLISTER PACK; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG PREFERENCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; QUALITY OF LIFE; SIDE EFFECT; TREATMENT DURATION; WEIGHT REDUCTION;

EID: 58349098578     PISSN: 02774208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Strader DB,Wright T, Thomas DL, et al. AASLD practice guideline: diagnosis, management, and treatment of Hepatitis C. Hepatology, 2004;39:1147-1171.
2. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements, 2002;19:1-46.
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus ribavirin for the initial treatment of chronic hepatitis C: a randomized trial. Lancet, 2001;358:958-965.
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. NEJM, 2002;347:975-982.
5. Shiffman ML. Side effects of medical therapy for chronic hepatitis C. Ann Hepatol, 2004;3:5-10.
6. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology, 2002;123:1061-1069.
7. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology, 2003;38:645-652.
8. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon Alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology, 2004;126:1015-1023.
9. Gulick RM. Adherence to Antiretroviral Therapy: How Much Is Enough? Clin Infect Dis, 2006;43:942-944.
10. Stone VE, Clarke J, Lovell J, et al. HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors. J Gen Intern Med, 1998;13:586-593.
11. Miller PD, Epstein S, Sedarati F, et al. Once-Monthly oral ibandronate compared with weekly oral alendronate in postmenopausal 0osteoporosis: MOTION study. Curr Med Res Opin, 2008;24:207-213.
12. Kamm MA, Sandborn WJ, Gassull M, et al. Once-Daily High Concentration MMX Mesalamine in Active Ulcerative Colitis. Gastroenterology, 2007;132:66-75.
13. Laederach-Hofmann K, Bunzel B. Noncompliance in organ transplant recipients: a literature review. Gen Hosp Psychiatry, 2000;22:412-424.
14. Marchesini G, Bianchi G, Amodio P, et al. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology, 2001;120:170-178.
15. Cordoba J, Flavia M, Jacas C, et al. Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol, 2003;39:231-238.
16. Chong CA, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol, 2003;98:630-638.
17. Younossi ZM, Guyatt G. Quality-of life assessments and chronic liver disease. Am J Gastroenterol, 1998;93:1037-1041.
18. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology, 1998;27:209-212.
19. Taliani G, Rucci P, Biliotti E, et al. Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection. J Viral Hepat, 2007;14:875-882.
20. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA, 2006;296:2563-2571.
21. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology, 1999;29:264-270.
22. Bernstein D, Kleinman L, Barker CM. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology, 2002;35:704-708.
23. Rodriguez-Torres M, Sulkowski M, Chung RT, et al. Association of pre-treatment and on-treatment factors with rapid virologic response in HCV genotype 1 infected patients treated with PegIFNà-2a/RBV. AASLD Nov 2-6, 2007. Boston, MA.
24. Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in HCV genotype 1 patients completing peginterferon 2a/ ribavirin treatment. Clin Gastroenterology Hepatol, 2007; 5:124-129.
25. Andriulli A, Cursaro C, Cozzolongo R, et al. Early Discontinuation of ribavirin in HCV 2 and 3 patients responding to peginterferon alfa 2a and ribavirin. AASLD Nov 2-6, 2007 Boston, MA.
26. Bronowicki JP, Ouzan D, Asselah T. Effect of ribavirin in genotype 1 patients with HCV responding to pegylated interferon alfa a plus ribavirin. Gastroenterology, 2006;131:1040-1048.